Georgios Vrachiolias

Alexandroupoli, ESYE11, Greece

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Excess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta-analysis.

Excess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta-analysis.

Journal: Cancer
Published: April 05, 2026

Detection of vascular amyloid deposits in a bone marrow aspirate.

Detection of vascular amyloid deposits in a bone marrow aspirate.

Journal: British journal of haematology
Published: March 09, 2026

Clonal Hematopoiesis of Indeterminate Potential (CHIP): A Model of Mutation-Driven Thromboinflammation.

Clonal Hematopoiesis of Indeterminate Potential (CHIP): A Model of Mutation-Driven Thromboinflammation.

Journal: Cancers
Published: March 08, 2026

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Journal: Blood advances
Published: July 14, 2025

Hans-Based Cell of Origin Is Not of Prognostic Significance in Diffuse Large B-Cell Lymphoma Patients: A Retrospective Single-Center Study Conducted in 326 RCHOP-Treated Patients.

Hans-Based Cell of Origin Is Not of Prognostic Significance in Diffuse Large B-Cell Lymphoma Patients: A Retrospective Single-Center Study Conducted in 326 RCHOP-Treated Patients.

Journal: Acta haematologica
Published: May 22, 2025

Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model.

Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model.

Journal: Annals of hematology
Published: January 24, 2025

Blood and platelet transfusion from a donor with presymptomatic Covid-19.

Blood and platelet transfusion from a donor with presymptomatic Covid-19.

Journal: Annals of hematology
Published: October 26, 2020

Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature.

Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature.

Journal: Mediterranean journal of hematology and infectious diseases
Published: August 17, 2020

Vacuolation of early erythroblasts with ring sideroblasts: a clue to the diagnosis of linezolid toxicity.

Vacuolation of early erythroblasts with ring sideroblasts: a clue to the diagnosis of linezolid toxicity.

Journal: British journal of haematology
Published: June 09, 2020

Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study.

Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study.

Journal: EJHaem
Published: May 12, 2020

Socioeconomic Status Is an Independent Prognostic Factor for Overall Survival in Patients With Multiple Myeloma: Real-World Data From a Cohort of 223 Patients.

Socioeconomic Status Is an Independent Prognostic Factor for Overall Survival in Patients With Multiple Myeloma: Real-World Data From a Cohort of 223 Patients.

Journal: Clinical lymphoma, myeloma & leukemia
Published: April 07, 2020
Showing 1-11 of 11

Last Updated: 09/26/2026